These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 8510277

  • 1. Cisplatin, methotrexate and vinblastine plus surgical restaging for patients with advanced transitional cell carcinoma of the urothelium.
    Miller RS, Freiha FS, Reese JH, Ozen H, Torti FM.
    J Urol; 1993 Jul; 150(1):65-9. PubMed ID: 8510277
    [Abstract] [Full Text] [Related]

  • 2. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium.
    Sternberg CN, Yagoda A, Scher HI, Watson RC, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N, Weiselberg LR.
    J Urol; 1988 Mar; 139(3):461-9. PubMed ID: 3343727
    [Abstract] [Full Text] [Related]

  • 3. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.
    Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N.
    Cancer; 1989 Dec 15; 64(12):2448-58. PubMed ID: 2819654
    [Abstract] [Full Text] [Related]

  • 4. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for extravesical urinary tract tumors.
    Scher HI, Yagoda A, Herr HW, Sternberg CN, Morse MJ, Sogani PC, Watson RC, Reuter V, Whitmore WF, Fair WR.
    J Urol; 1988 Mar 15; 139(3):475-7. PubMed ID: 3343729
    [Abstract] [Full Text] [Related]

  • 5. Methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) for advanced TCC of urothelium.
    Huang CH, Hsieh HH, Wang JM, Hsu K, Yang WC, Yu TJ.
    J Formos Med Assoc; 1992 Jul 15; 91(7):699-703. PubMed ID: 1360298
    [Abstract] [Full Text] [Related]

  • 6. Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin chemotherapy for advanced urothelial cancers.
    Ogawa T, Gotoh A, Takenaka A, Hara I, Gohji K, Arakawa S, Matsumoto O, Kamidono S.
    Cancer Chemother Pharmacol; 1992 Jul 15; 30 Suppl():S66-71. PubMed ID: 1394822
    [Abstract] [Full Text] [Related]

  • 7. Chemotherapy of urothelial tract tumors.
    Yagoda A.
    Cancer; 1987 Aug 01; 60(3 Suppl):574-85. PubMed ID: 3297286
    [Abstract] [Full Text] [Related]

  • 8. [Clinical evaluation of M-VAC chemotherapy (methotrexate, vinblastine, adriamycin and cisplatin) for advanced urothelial cancer].
    Gohji K, Takenaka A, Goto A, Hara I, Matsumoto O, Kamidono S, Hamami G, Itani A, Harada K, Tadera N.
    Nihon Hinyokika Gakkai Zasshi; 1989 Mar 01; 80(3):321-8. PubMed ID: 2659869
    [Abstract] [Full Text] [Related]

  • 9. [Methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer--analysis of efficacy and toxicity].
    Igawa M, Kadena H, Ohkuchi T, Ueda M, Usui T.
    Nihon Hinyokika Gakkai Zasshi; 1991 Oct 01; 82(10):1627-36. PubMed ID: 1770701
    [Abstract] [Full Text] [Related]

  • 10. [Gemcitabine/cisplatin vs. MVAC. 5 year survival outcome of the phase III study of chemotherapy of advanced urothelial carcinoma in Germany].
    Lehmann J, Retz M, Steiner G, Albers P, Jaeger E, Knuth A, Lippert C, Koser M, Stockamp K, Otto C, Melchior H, Fassmann C, Potratz C, Loch T, Derigs HG, Becker T, Kälble T, Piechota HJ, Hertle L, Weinknecht S, Weissbach L, Al-Mwalad M, Hamza A, Henss H, Brkovic D, Pomer S, Roloff J, Walz P, Muschter R, Tunn U, Winter E, Bub P, Kaldenbach U, Roth S, Brauers A, Jakse G, Richter AE, Wirth M, Hartlapp J, Van Ahlen H, Stöckle M.
    Urologe A; 2003 Aug 01; 42(8):1074-86. PubMed ID: 14513232
    [Abstract] [Full Text] [Related]

  • 11. A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party.
    Mead GM, Russell M, Clark P, Harland SJ, Harper PG, Cowan R, Roberts JT, Uscinska BM, Griffiths GO, Parmar MK.
    Br J Cancer; 1998 Oct 01; 78(8):1067-75. PubMed ID: 9792152
    [Abstract] [Full Text] [Related]

  • 12. [Experience with combination chemotherapy consisting of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer].
    Nishio Y, Shirahase T, Shichiri Y, Habuchi T, Matsuda T, Nishimura K, Hida S, Okada Y, Yoshida O.
    Hinyokika Kiyo; 1988 Aug 01; 34(8):1371-5. PubMed ID: 3195405
    [Abstract] [Full Text] [Related]

  • 13. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium.
    Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR, Geller N, Hollander PS, Herr HW, Sogani PC.
    J Urol; 1985 Mar 01; 133(3):403-7. PubMed ID: 4038749
    [Abstract] [Full Text] [Related]

  • 14. Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma.
    Dodd PM, McCaffrey JA, Mazumdar M, Scher H, Vlamis V, Higgins G, Herr H, Bajorin DF.
    Cancer; 1999 Mar 01; 85(5):1145-50. PubMed ID: 10091800
    [Abstract] [Full Text] [Related]

  • 15. [Combination chemotherapy with M-VAC protocol in metastatic urothelial cancer].
    Sella A, Flex D, Gafni D, Rabinovitz O, Sulkes A, Baniel J.
    Harefuah; 1999 Feb 15; 136(4):268-71, 340, 339. PubMed ID: 10914214
    [Abstract] [Full Text] [Related]

  • 16. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
    McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Heineman M, Hirsch J, Kelly WK, Scher HI, Bajorin DF.
    J Clin Oncol; 1997 Jun 15; 15(6):2449-55. PubMed ID: 9196161
    [Abstract] [Full Text] [Related]

  • 17. [Systemic chemotherapy for transitional cell carcinoma of the urothelium].
    Lehmann J, Retz M, Hack M, Siemer S, Stöckle M.
    Onkologie; 2003 Oct 15; 26 Suppl 4():18-25. PubMed ID: 14605452
    [Abstract] [Full Text] [Related]

  • 18. Cisplatin-based chemotherapy for the treatment of advanced transitional-cell carcinoma of the urinary tract--a preliminary report.
    Lee MH, Chen MT, Chen KK, Lin AT, Lee YH, Lee LM, Chang YM, Chang LS, Liu JM, Hsieh RK.
    Cancer Chemother Pharmacol; 1992 Oct 15; 30 Suppl():S81-4. PubMed ID: 1394825
    [Abstract] [Full Text] [Related]

  • 19. Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.
    De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, Skoneczna I, Marreaud S, de Wit R, Sylvester R.
    J Clin Oncol; 2009 Nov 20; 27(33):5634-9. PubMed ID: 19786668
    [Abstract] [Full Text] [Related]

  • 20. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.
    Harker WG, Meyers FJ, Freiha FS, Palmer JM, Shortliffe LD, Hannigan JF, McWhirter KM, Torti FM.
    J Clin Oncol; 1985 Nov 20; 3(11):1463-70. PubMed ID: 4056840
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.